Immunological responses to adjuvant vaccination with combined CD1c <sup>+</sup> myeloid and plasmacytoid dendritic cells in stage III melanoma patients
Martine Bloemendal, Kalijn F. Bol, Steve Boudewijns, Mark A.J. Gorris, Johannes H.W. de Wilt, Sandra Croockewit, Michelle M. van Rossum, Anna L. de Goede, Katja Petry, Rutger H.T. Koornstra, Carl G. Figdor, Winald R. Gerritsen, Gerty Schreibelt, I. Jolanda M. de Vries
Abstract
T cells were detectable in peripheral blood. Functional interferon-γ-producing T cells were found in the skin test of 64% of the patients. Production of nDC vaccines meeting release criteria was feasible for all patients. Vaccination only induced grade 1-2 adverse events, mainly consisting of fatigue. In conclusion, adjuvant dendritic cell vaccination with cDC2s and/or pDCs is feasible, safe and induced immunological responses in the majority of stage III melanoma patients.
Topics & Concepts
AdjuvantDendritic cellMedicineImmunologyCD8Plasmacytoid dendritic cellVaccinationAntigenMelanomaImmunotherapyAntigen-presenting cellMyeloidImmune systemLymph nodeT cellCancer researchImmunotherapy and Immune Responsesvaccines and immunoinformatics approachesT-cell and B-cell Immunology